RE:RE:RE:RE:RE:RE:RE:RE:RE:Observations & QuestionsMacer wrote:
we can expect the same pace of enrollement for phase 2, although we likely don;t have to wait for single patient safety data before proceeding to the next patient. With each clinical site added we will shorten the clinical trial period due to increased enrollement. So if the raise is able to reach 15 million and expand into Europe we will see an accelerated timeline.
To me, if there is interest enough to raise 15 million it tells me we are in for a more interesting ride!
Macer
Working out a deal for the full $15 million shouldn't be a problem if you lower the price of the PP shares and offer cheap warrants. The capital markets are going to want an extra incentive if they are going to fund the phase 2 trial for the next 29 months. That's why I doubt the prospectus will be fully subscribed at market prices. Money talks and if the company expects the capital markets to support the phase 2 trial to practically its estimated end then they expect something back in return. That's just the way business operates. For the company an oversubscibed prospectus would be ideal as it would allow them to concentrate on the commercialization of the science while not worrying about cash for the next 3 years.